Related Experiment Video
Updated: Oct 13, 2025
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Controversies surrounding peripheral cannabinoid receptor 1 in fatty liver disease
Beste Mutlu1,2, Pere Puigserver1,2
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Abstract:
Cannabinoid receptor 1 (CB-1) antagonists are potential candidates for treating obesity and metabolic complications. Despite clear metabolic benefits, unwanted side effects in the brain pose issues for patients. With the hope of overcoming this obstacle, CB-1 in peripheral tissues has become a potential drug target. Previous studies had suggested that liver CB-1 would be an excellent target to prevent development of nonalcoholic steatohepatitis (NAFLD). However, in this issue of the JCI, Wang et al. showed that CB-1 was barely detectable in the liver and deletion of CB-1 in hepatocytes provided no metabolic benefits against NAFLD. These contradictory results raise substantial concerns about the potential benefits of peripheral CB-1 blockers against NAFLD.
Insights
Blocking cannabinoid receptor 1 (CB-1) in the liver does not appear to benefit nonalcoholic steatohepatitis (NAFLD). New research indicates CB-1 is minimally present in liver cells, challenging its use as a therapeutic target for metabolic disorders.
Area of Science:
- Metabolic disorders
- Hepatology
- Pharmacology
Background:
- Cannabinoid receptor 1 (CB-1) antagonists show promise for obesity and metabolic issues.
- Brain-related side effects limit therapeutic use.
- Targeting peripheral CB-1, particularly in the liver, is explored for nonalcoholic steatohepatitis (NAFLD).
Purpose of the Study:
- To investigate the role of liver CB-1 in the development of NAFLD.
- To evaluate the therapeutic potential of blocking liver CB-1 for NAFLD.
Main Methods:
- Assessed CB-1 expression levels in liver tissue.
- Examined the metabolic effects of hepatocyte-specific CB-1 deletion in a NAFLD model.
Main Results:
- CB-1 expression was found to be minimal in hepatocytes.
- Deletion of CB-1 in hepatocytes did not confer metabolic benefits against NAFLD.
- Contradicts previous suggestions of liver CB-1 as a viable NAFLD target.
Conclusions:
- Current evidence suggests limited potential for peripheral CB-1 blockers targeting the liver in NAFLD treatment.
- Further research is needed to clarify the role of CB-1 in liver metabolism and NAFLD pathogenesis.
More Related Videos
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:35A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
Published on: May 18, 2021
Related Concept Videos
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:28Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):